Working… Menu
Trial record 7 of 8 for:    "Bone Disease" | "Methadone"

Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04112550
Recruitment Status : Not yet recruiting
First Posted : October 2, 2019
Last Update Posted : October 2, 2019
Information provided by (Responsible Party):
SBarber, The Methodist Hospital System

Brief Summary:

Spinal operations including lumbar fusions for degenerative disorders are becoming more prevalent as the population ages. Inadequate or excessive postoperative analgesia can result in medical comorbidities and prolonged hospital length of stay and patient dissatisfaction.

Existing literature has highlighted the preoperative administration of methadone as a promising adjuvant for post operative pain control. Methadone has the benefit of being long-acting and has more stable serum concentration and a single preoperative dose may have significant benefits post operatively.

Here the investigators propose a prospective parallel-group, randomized, double-blinded study to assess post operative analgesic requirements after preoperative administration of either methadone 15 mg or Oxycodone 10/325. Primary outcome will be total IV and PO narcotic consumption in the post operative course. Secondary outcomes examined will include time to mobility, need for specialist pain management consultation, early readmission (within 2 weeks) for inadequate pain control, and complications associated with administration.

Condition or disease Intervention/treatment Phase
Degenerative Disc Disease Spondylolisthesis, Lumbar Region Drug: Methadone Hydrochloride Drug: Oxycodone-Acetaminophen Phase 1

Detailed Description:

Lumbar spinal fusions are becoming increasingly popular and prevalent in the treatment of a variety of spinal pathologies, but predominantly for degenerative disease which is most prevalent in the obese and or older population. These operations can result in relatively high post operative surgical pain and necessitate significant post operative opioid consumption which can precipitate co-morbid medical conditions such as respiratory depression and failure, pneumonia, gastrointestinal ileus, deep venous thrombosis, and pulmonary embolism. Additionally, these medical comorbidities also represent an increased burden on healthcare expenditure with increased length of hospital stay, inpatient testing and treatment, and need for additional follow up.

The investigators objective is to study the effect of a long term opioid analgesic, methadone, in a uniform population undergoing a single level minimally invasive lumbar fusion. The preoperative single dose administration of methadone has already been shown to be effective in improving post operative pain control in open multi-level spinal fusion patient populations and has become the standard of care in most surgical centers across the country. The long half-life of methadone results in improved steady state pharmacokinetics relative to other traditional opioids and is thought to improve pain control while decreasing consumption. In addition to Mu opioid receptor agonism, Methadone is thought to also have adjunctive analgesic and anti-tolerance effects due to CNS excitatory glutamatergic NMDA receptor antagonism. There are also reports of synergistic effects from serotonin and norepinephrine reuptake inhibition.

The investigators predict that a single preoperative oral methadone administration can result in improved postoperative analgesia with requirement of less IV and PO traditional narcotics within the first 2 weeks post operatively and also will not increase co-morbid risks relative to traditional shorter acting opioid analgesics that are presently given preoperatively.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions: A Randomized, Double-blinded, Controlled Trial
Estimated Study Start Date : November 1, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Arm Intervention/treatment
Active Comparator: Methadone
This cohort will receive oral methadone 15mg po tablet pre-operatively
Drug: Methadone Hydrochloride
FDA approved medication to treat pain

Active Comparator: Oxycodone
This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
Drug: Oxycodone-Acetaminophen
FDA approved medication to treat pain

Primary Outcome Measures :
  1. Post-operative in-hospital patient's narcotic requirement [ Time Frame: Post-operative day 0 to 4 ]
    The total Morphine Milligram Equivalent (MME) for each post-operative day

  2. Improvement in low back pain between the two cohorts as assessed by Oswestry Disbility Index (ODI) [ Time Frame: 14 days ]
    Change in ODI (scale from 0 to 100) from pre-op to post-op (14 days post-op)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age: 18 - 70
  • Will undergo one level minimally invasive lumbar fusion surgery
  • Primary symptoms are back and/or leg pain

Exclusion Criteria:

  • Preoperative chronic renal insufficiency or failure (defined as a serum creatinine more than 2 mg/dl)
  • Significant liver disease (cirrhosis or hepatic failure)
  • American Society of Anesthesiologists (ASA) physical status IV or V
  • Pulmonary disease necessitating home oxygen therapy
  • Patients with acute bronchial asthma or hypercarbia
  • Patient who has or is suspected of having a paralytic ileus
  • Preoperative use of methadone or hydromorphone
  • Known hypersensitivity to methadone
  • Known hypersensitivity to oxycodone
  • Recent history of opioid or alcohol abuse
  • Inability to use a PCA device
  • Inability to speak English
  • Any patient judged by the anesthesia care team to potentially require prolonged postoperative intubation
  • Participation in another clinical trial
  • Inability of patient to provide study informed consent (including patients who are cognitively impaired)
  • Presence of drug interaction between methadone/oxycodone and patient's regular or PRN medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04112550

Layout table for location contacts
Contact: Saeed S Sadrameli, MD, MS 2817431385
Contact: Marcus S Wong, MD 8324574452

Sponsors and Collaborators
The Methodist Hospital System
Layout table for investigator information
Principal Investigator: Sean M Barber, MD Houston Methodist

Layout table for additonal information
Responsible Party: SBarber, Neurosurgery Faculty, The Methodist Hospital System Identifier: NCT04112550     History of Changes
Other Study ID Numbers: Pro00022567
First Posted: October 2, 2019    Key Record Dates
Last Update Posted: October 2, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: No plans to share IPD at the moment

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by SBarber, The Methodist Hospital System:
lateral lumbar interbody fusion
minimally invasive spinal surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases
Intervertebral Disc Degeneration
Spinal Diseases
Musculoskeletal Diseases
Acetaminophen, hydrocodone drug combination
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Analgesics, Opioid
Central Nervous System Depressants
Antitussive Agents
Respiratory System Agents
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents